Published in final edited form as:

Metallomics. 2014 March 26; 6(3): 476–490. doi:10.1039/c3mt00325f.

The effects of *pdr1*, *djr1.1* and *pink1* loss in manganese-induced toxicity and the role of α -synuclein in *C. elegans*

Julia Bornhorst^{a,b,§}, Sudipta Chakraborty^{b,c,§}, Sören Meyer^{a,d}, Hanna Lohren^a, Sigrid Große Brinkhaus^e, Adam L. Knight^f, Kim A. Caldwell^f, Guy A. Caldwell^f, Uwe Karst^e, Tanja Schwerdtle^a, Aaron Bowman^g, and Michael Aschner^{b,h,i}

^aInstitute of Food Chemistry, University of Münster, Münster, Germany

^bDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA

^cNeuroscience Graduate Program, Vanderbilt University Medical Center, Nashville, TN, USA

^dGraduate School of Chemistry, University of Münster, Münster, Germany

^eInstitute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany

^fDepartment of Biological Sciences, University of Alabama, Tuscaloosa, AL, USA

^gDepartment of Neurology, Vanderbilt Kennedy Center, Center for Molecular Toxicology, Vanderbilt University Medical Center, Nashville, TN, USA

^hDepartment of Pharmacology, the Kennedy Center for Research on Human Development, and the Center for Molecular Toxicology, Vanderbilt University Medical Center, Nashville, TN, USA

ⁱDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Forchheimer 209, 1300 Morris Park Avenue, Bronx, NY 10461, Tel: 718.430.2317, Fax: 718.430.8922, Michael.Aschner@einstein.yu.edu

Abstract

Parkinson's disease (PD) is a neurodegenerative brain disorder characterized by selective dopaminergic (DAergic) cell loss that results in overt motor and cognitive deficits. Current treatment options exist to combat PD symptomatology, but are unable to directly target its pathogenesis due to a lack of knowledge concerning its etiology. Several genes have been linked to PD, including three genes associated with an early-onset familial form: *parkin*, *pink1* and *djl*. All three genes are implicated in regulating oxidative stress pathways. Another hallmark of PD pathophysiology is Lewy body deposition, associated with the gain-of-function genetic risk factor α -synuclein. The function of α -synuclein is poorly understood, as it shows both neurotoxic and neuroprotective activities in PD. Using the genetically tractable invertebrate *Caenorhabditis elegans* (*C. elegans*) model system, the neurotoxic or neuroprotective role of α -synuclein upon acute Mn exposure in the background of mutated *pdr1*, *pink1* or *djr1.1* was examined. The *pdr1* and *djr1.1* mutants showed enhanced Mn accumulation and oxidative stress that was rescued by α -synuclein. Moreover, DAergic neurodegeneration, while unchanged with Mn exposure, returned to wild-type (WT) levels for *pdr1*, but not *djr1.1* mutants expressing α -synuclein. Taken together, this study uncovers a novel, neuroprotective role for WT human α -synuclein in attenuating Mn-induced toxicity in the background of PD-associated genes, and further supports the role of extracellular dopamine in exacerbating Mn neurotoxicity.

Introduction

Parkinson's disease (PD) is the second most common neurodegenerative disorder in the U.S., affecting nearly 1% of the population ¹.

With an age of onset typically around 60 years of age, this disease manifests a selective dopaminergic (DAergic) neuronal loss in the substantia nigra pars compacta (SNpc), resulting in overt motor and cognitive deficits ². The cardinal motor symptomatology of PD includes bradykinesia, rigidity, tremors and postural instability that may be preceded by emotional instability and cognitive problems ³. As age remains the most significant risk factor for PD pathogenesis, the ever-increasing human lifespan has produced a financial and emotional burden worldwide. Untenable treatment options that do not target the etiology of PD are a major public health concern, and warrant further investigations into the specific mechanisms behind PD pathophysiology.

While the majority of PD cases are idiopathic, many genes have now been associated with the disease, including *DJ1*, *PINK1*, *parkin*, *NURR1*, *LRRK2*, *UCH-L1*, and *α -synuclein* ³. The current study focuses on the major early-onset, familial PD genes: *parkin*, *pink1* and *dj1*. Homozygous mutations in the *PARK2/parkin* gene are responsible for nearly 50% of an autosomal recessive, early-onset, familial form of PD ⁴. This gene encodes for an E3 ubiquitin ligase involved in the ubiquitin proteasome system (UPS) that targets substrates for degradation ⁵. Mutations in this gene result in impaired ligase activity and substrate binding that can lead to increased protein aggregation ⁶. *Parkin* knockout (KO) models show a variety of PD-associated phenotypes, including hypokinetic deficits, DAergic cell loss ⁷ and increased extracellular dopamine (DA) levels in the striatum ⁸.

The PD-associated protein known as PINK1, or PTEN-induced kinase 1, is a mitochondrial-targeted protein that contains a highly conserved serine/threonine kinase domain ⁹. Homozygous mutations in *pink1* are also connected to autosomal recessive, early-onset PD ¹⁰. These mutations typically result in impaired kinase activity ¹¹ that is otherwise critical for maintaining mitochondrial integrity, as phosphorylation targets include mitochondrial fission and fusion factors ¹², as well as the mitochondrially-located serine protease HtrA2 ¹³. Wildtype PINK1 has been shown to protect against mitochondrial toxin-induced DAergic cell death, as well as reducing apoptotic caspase levels and mitochondrial cytochrome c release ¹⁴. *pink1* mutants show increased DAergic cell death ¹⁵ and impaired DA release ¹⁶.

Recent studies have identified parkin as a PINK1 phosphorylation target. In fact, these two proteins work in parallel to promote mitophagy through a PINK1-mediated phosphorylation (and autophosphorylation) and recruitment of parkin to mitochondria with a lowered membrane potential ¹⁷. Various modulators of this interaction have recently been introduced, including the mitochondrial fusion factor Mitofusin 2 (Mfn2) and voltage-dependent anion channels (VDACs) ¹⁸. This novel role for both parkin and PINK1 reveals the importance of maintaining proper mitochondrial trafficking and turnover, signifying an impaired clearance of defective mitochondria as a potential mechanism in the pathophysiology of PD.

Additionally, mutations in the *PARK7/dj1* gene are also associated with autosomal recessive, early-onset PD ¹⁹. This gene encodes for a protein that functions as an oxidative stress sensor, where oxidation of a cysteine residue results in translocation of the acidic isoform from the cytoplasm to mitochondria ²⁰. Mutations in *dj1* result in increased ROS levels, impaired mitochondrial energetics ²¹ and DAergic cell death, while overexpression protects against DA toxicity and cell loss ²². DJ1 has also been shown to form a multi-protein

complex with parkin and PINK1²³, though this remains controversial. Moreover, DJ1 up-regulation can rescue the loss of PINK1-mediated sensitization of DAergic neurons in the SNpc to a mitochondrial toxin²⁴. The rescue of *pink1* loss-mediated mitochondrial deficits by DJ1 was also seen in *Drosophila*, but showed no rescue in *parkin* mutants²⁵. This data reveal a role of DJ1 acting in parallel with the parkin/PINK1 pathway.

Another gene implicated in PD pathophysiology is *SNCA*²⁶ that encodes for α -synuclein (α -Syn), the major aggregated component of Lewy body depositions. Pathogenic mutations in the *SNCA* gene have been shown to promote increased aggregation of the protein²⁷. While the function of α -Syn remains unclear, high expression is found in neuronal presynaptic terminals. Recent evidence has implicated α -Syn in regulating synaptic vesicle release, mobility and recycling²⁸, along with decreased DA release from vesicles in the background of α -Syn overexpression²⁹. Wildtype α -Syn has been shown to inhibit tyrosine hydroxylase (TH) activity, suggesting a physiological role in controlling optimal DA biosynthesis³⁰. However, aggregated forms are no longer able to inhibit TH activity, with higher TH phosphorylation present³¹. Elucidating the role of wildtype α -Syn in the background of other PD genes may provide deeper insight into the neuroprotective or neurotoxic nature of α -Syn in PD.

While genes such as *SNCA*, *parkin*, *pink1* and *dj1* may be associated with PD, the heterogeneity in age-of-onset, as well as 90% of cases being sporadic in nature, warrants investigation into the role of environmental factors in PD etiology. One such factor is manganese (Mn). This is an essential trace element that is necessary for proper immune function, bone growth, digestion, reproduction, as well as serving as an important cofactor for many enzymes³². However, overexposure can result in symptomatology that resembles PD³³. Environmental sources of Mn exposure can include drinking water (groundwater), pesticides, manufacturing by-products, and airborne exposure upon combustion of the fuel additive methylcyclopentadienyl manganese tricarbonyl (MMT). However, excessive occupational Mn exposure may also arise from welding, steel mining, smelting, and other industrial occupations³⁴. Several studies have already begun to examine gene-environment interactions between Mn exposure and PD-associated genes. For example, rats exposed to Mn-containing welding fumes show an increase in parkin protein levels³⁵; parkin was also shown to selectively protect against Mn-induced DAergic cell death *in vitro*³⁶.

In this work, the tractable, invertebrate *Caenorhabditis elegans* (*C. elegans*) model system expressing human wildtype α -Syn was used for the first time to examine the roles of several early-onset, PD-associated genes (*pdr1*, *pink1* and *dj1.1*) and α -Syn in mediating Mn-induced neurotoxicity. Thereby, Mn uptake and Mn-induced oxidative stress in the background of mutated *pdr1*, *pink1* and *dj1.1* are illustrated. Furthermore, this paper demonstrates a novel role for α -Syn in altering Mn accumulation in the background of mutated genes (*pdr1* and *dj1.1*) through the utilization of inductively coupled plasma-mass spectrometry (ICP-MS/MS), as well as visualizing intraworm Mn levels by laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS).

Experimental

C. elegans Strains and Handling

C. elegans strains were handled and maintained at 20°C as previously described³⁷. The following control strains were used: N2, wildtype (*Caenorhabditis* Genetics Center, CGC); and BY200, *p_{dat-1}::GFP(vtIs1)* V (kindly provided by the Blakely laboratory, Vanderbilt University Medical Center). The following deletion mutants were used: VC1024, *pdr1(gk448)* III (CGC); *pink1(tm1779)* II; and *dj1.1(tm918)* II. These deletion strains were also crossed with the BY200 strain for GFP control studies. The following α -synuclein-

containing strains were kindly provided by the Caldwell laboratory (University of Alabama): UA44, *p_{dat-1}::α-syn, p_{dat-1}::GFP[baIn11]*; UA88, *pdr1(tm598), p_{dat-1}::α-syn, p_{dat-1}::GFP[baIn11]*; UA84, *djrl.1(tm918), p_{dat-1}::α-syn, p_{dat-1}::GFP[baIn11]*; and UA86, *pink-1(tm1779); p_{dat-1}::GFP; p_{dat-1}::α-syn [baIn11]*.

Preparation of MnCl₂

MnCl₂ (>99.995 % purity) (Sigma-Aldrich) stock solutions were prepared in 85 mM NaCl. To prevent oxidation, fresh stock solutions were prepared shortly before each experiment.

Acute Mn Treatments and Mn-Induced Lethality Assay

2,500 synchronized L1 worms per tube were acutely exposed to MnCl₂ in triplicates in siliconized tubes for 30 minutes. Worms were then pelleted by centrifugation at 7,000 rpm for 3 minutes and washed four times in 85 mM NaCl. 30-50 worms were then pre-counted and transferred to OP50-seeded NGM plates and blinded. The total number of surviving worms was scored 48 hours post treatment.

Mn Quantification in *C. elegans*

Mn content was determined after ashing of L1 worms by ICP-MS/MS. Briefly, 50,000 synchronized L1 worms were acutely treated with MnCl₂. Worms were pelleted, washed five times in 85 mM NaCl and re-suspended in 1 mL 85 mM NaCl supplemented with 1% protease inhibitor. After sonication, an aliquot was taken for protein quantification using the bicinchoninic acid (BCA) assay-kit (Thermo Scientific). Subsequently, the suspension was mixed again, evaporated, and incubated with the ashing mixture (65% HNO₃/30% H₂O₂ (1/1) (both from Merck)) at 95°C for at least 12 h. After dilution of the ash with 2% HNO₃ including 10 µg/L Rh as internal standard to compensate drift effects, the Mn concentration was determined by ICP-MS/MS (Agilent 8800 ICP-QQQ). The nebulizer gas flow and parameters of lenses, Q1, collision cell and Q2 were tuned daily on a daily basis for maximum sensitivity (an oxide ratio of <1.0% (¹⁴⁰Ce⁶⁰⁺/¹⁴⁰Ce⁺) and a double charged ratio of <1.5% (¹⁴⁰Ce⁺⁺/¹⁴⁰Ce⁺) with background counts <0.1 cps) (Table 1). The limit of quantification (LOQ) for Mn was 0.10 µg/L calculated according to the 3σ-criterion³⁸. Determinations of blank and certified reference material (CRM 414 (plankton) (Community Bureau of Reference of the Commission of the European Communities)) were performed periodically after 15 samples each.

Additionally, the Mn content was qualitatively confirmed by LA-ICP-MS analyses. Briefly, 50,000 synchronized L1 worms acutely exposed to MnCl₂ were pelleted and washed three times with 85 mM NaCl and two times with bidistilled water. Worms were prepared for analyses by drying single worms on microscopic slides (Thermo Scientific).

The laser ablation system LSX213G2+ (CETAC Technologies) was coupled to an ICP-MS (ICAP Qc, Thermo Fisher Scientific). Slides were placed in the ablation chamber and ablated linewise using a quintupled Nd:YAG laser (wavelength 213 nm, repetition frequency 20 Hz spot, spot diameter 4 µm). The ablated material was transported into the ICP-MS by the carrier gas (He/Ar) and analytes were determined using the MS in KEDS mode (Table 2,3). In addition, a 10 µg/L Rh-solution including 2% HNO₃ was continuously delivered into ICP via a cyclonic spraychamber to compensate drift effects during analysis.

Dopaminergic Degeneration Assay

Synchronized L1 worms (2500/per tube) were acutely exposed to MnCl₂. Upon washing, all worms were plated on OP50-seeded NGM plates. Forty eight hours post-treatment, 50 worms were transferred to fresh OP50-seeded NGM plates and blinded for subsequent

imaging. At 72 hours post-treatment, 15 worms per condition were mounted onto 4% agar pads (in M9 buffer) and anesthetized with 0.2% tricaine/0.02% tetramisole in M9 buffer. Scoring of neuronal defects was performed using an epifluorescence microscope (Nikon Eclipse 80i) equipped with a Lambda LS Xenon lamp (Sutter Instrument Company) and Nikon Plan Fluor 20x dry and Nikon Plan Apo 60x 1.3 oil objectives. Each worm was scored for the absence (“normal”) or presence of any of the following morphological changes: puncta formation along dendritic processes; shrunken soma; and/or loss of soma and/or dendrites (“degenerated”). Representative confocal images (Carl Zeiss MicroImaging, Inc.) of each morphological phenotype were taken and processed as previously described³⁹.

RONS Measurement

The formation of reactive oxygen and nitrogen species (RONS) in whole L1 worms was evaluated by a 5(6)-Carboxy-2',7'-dichlorodihydrofluorescein-diacetate (carboxy-DCFH-DA)-based plate reader system. Briefly, a carboxy-DCFH-DA stock solution (50 mM in DMSO) (Invitrogen) was diluted 1:100 with M9 buffer, and synchronized L1 worms were exposed to 500 μ M for 1 h in the dark. After 1 h, the worms were washed two times with M9 buffer and two times with 85 mM NaCl to remove all carboxy-DCFH-DA content outside the worm. 10,000 worms were transferred to each well of a 96-well plate and incubated with H₂O₂ (positive control) or MnCl₂ (respective LD₂₅ concentration). Immediately after incubation, the intracellular oxidation of carboxy-DCFH, which correlates with intracellular RONS, was monitored (excitation 485 nm/emission 535 nm) by a microplate reader (FLUOstar Optima microplate reader, BMG Labtechnologies), and kinetics were constructed up to 420 min. To exclude interfering fluorescence of the matrix, data were normalized to a control (dye-loaded cells without a RONS generator).

Glutathione Quantification

Total intracellular glutathione levels (reduced and oxidized GSH) were determined with the “enzymatic recycling assay”, as previously described⁴⁰. Briefly, whole worm extracts were prepared out of 50,000 L1 worms acutely exposed to MnCl₂. This was followed by washes with 85 mM NaCl and sonication of the pellet in 0.1 mL ice cold extraction buffer (1% Triton X-100, 0.6% sulfosalicylic acid) and 1% protease inhibitor in KPE buffer (0.1 M potassium phosphate buffer, 5 mM EDTA). Intracellular GSH was quantified by measuring the change in absorbance per minute at 412 nm by a microplate reader after reduction of 5,5'-dithio-2-nitrobenzoic acid (DTNB, Sigma-Aldrich).

TaqMan Gene Expression Assay

Total RNA was isolated via the Trizol method. Briefly, following treatment, 1 mL of Trizol (Life Technologies) was added to each tube containing worms resuspended in 100 μ L 85 mM NaCl, followed by three cycles of freezing in liquid nitrogen and thawing at 37°C. 200 μ L of chloroform was then added to each tube, followed by precipitation using isopropanol and washing with 75% ethanol. Following isolation, 1 μ g total RNA was used for cDNA synthesis using the High Capacity cDNA Reverse Transcription Kit (Life Technologies), per manufacturer's instructions. cDNA samples were stored at 4°C. Quantitative real-time PCR (BioRad) was conducted in duplicate wells using TaqMan Gene Expression Assay probes (Life Technologies) for each gene, using the *afd-1* (*actin* homolog) housekeeping gene for normalization after determining the fold difference using the comparative 2^{- $\Delta\Delta$ Ct} method⁴¹. The following probes were used: human *dat-1* (Assay ID: Ce02450891_g1); *skn-1* (Assay ID: Ce02407447_g1); and *afd-1* (Assay ID: Ce02414573_m1).

Statistics

Dose-response lethality curves and all histograms were generated using GraphPad Prism (GraphPad Software Inc.). A sigmoidal dose-response model with a top constraint at 100% was used to draw the lethality curves and determine the respective LD₅₀ values (values represent the respective Mn concentrations that induce 50% reduction in survival), followed by a one-way analysis of variance (ANOVA) with a Dunnett's *post-hoc* test to compare all strains to their respective control strains. In order to compare all α -Syn to non- α -Syn-containing strains, a one-way ANOVA using Bonferroni's multiple comparison *post-hoc* test was conducted. Two-way ANOVAs were performed on metal content, RONS, GSH and TaqMan gene expression data, followed by Bonferroni's multiple comparison *post-hoc* tests. Degeneration data was plotted as a stacked histogram and analyzed using an unpaired t-test between groups (vs. respective control strains).

Results

pdr1 mutants are hypersensitive to acute Mn exposure

Assessment of dose-response survival curves following acute Mn exposure revealed a leftward-shift in the curve for *pdr1* mutant worms compared to N2 wild-type (WT) worms (fig. 1A).

Thus, *pdr1* mutants exhibited hypersensitivity to Mn-induced lethality (LD₅₀ = 5.59 mM) compared to WT worms (LD₅₀ = 10.43 mM). *djr1.1* mutants were less sensitive to acute Mn exposure vs. WT worms. *djr1.1*, one of the two *djr*-orthologues, shows the highest homology to vertebrate *djl* and broadest expression (similar to the other deletion mutants)⁴². Therefore, all studies were carried out in the *djr1.1* orthologue. Treating worms containing human WT α -Syn in addition to the respective genetic deletions (*pdr1*, *pink* and *djr1.1*) with Mn led to increased sensitivity compared to the WT α -Syn control strain (fig. 1B). One-way ANOVA analysis (comparing data from fig. 1A and B) showed a significantly increased sensitivity of the α -Syn-containing *djr1.1* mutants towards Mn compared to the *djr1.1* mutants alone (fig. 1C).

Enhanced Mn accumulation in *pdr1* and *djr1.1* mutants is attenuated by WT α -Syn expression

To determine whether a genetic deletion and/or the presence of WT α -Syn alters Mn bioavailability in *C. elegans*, Mn content was measured by ICP-MS/MS. Overall, the analyzed strains (fig. 2 A, B) showed a dose-dependent increase in Mn content (two-way ANOVA, concentration $p < 0.0001$). The *pdr1* and *djr1.1* deletion mutants exhibited an enhanced Mn accumulation compared to WT worms (fig. 2A). *pink1* mutants showed Mn accumulation that was indistinguishable from WT worms (fig. 2A). Notably, the *pdr1* and *djr1.1* mutants containing α -Syn accumulated less Mn compared to the respective deletion mutants alone (fig. 2C, D). While the rescue effect was not significant for the *pdr1* mutants (fig. 2C), the decrease in accumulation was significant at 7.5 and 10 mM Mn for the *djr1.1* mutants (fig. 2D). Moreover, we qualitatively confirmed the intraworm Mn accumulation using LA-ICP-MS. WT and *djr1.1* mutants, with and without α -Syn, were treated acutely with LD₅₀ dose (10 mM) (fig. 1). The images corroborate the ICP-MS/MS metal content analyses, showing increased Mn accumulation in the *djr1.1* mutants compared to the α -Syn-containing *djr1.1* mutants (fig. 2E).

Absence of Mn-induced DAergic neurodegeneration

Next, we determined whether the aforementioned Mn concentrations induce dopaminergic (DAergic) neurodegeneration. Visualization of the architecture of the four cephalic (CEP)

DAergic neurons in the head was performed using worms expressing green fluorescent protein (GFP) under the control of a promoter for the dopamine re-uptake transporter 1 (*C. elegans* orthologue for vertebrate DAT⁴³), *p_{dat-1}::GFP (vtIs1)*. Using an objective scoring system, the CEP neurons were scored as degenerated if they exhibited any of the following: discontinuous, punctated GFP signal in the dendrites (3A, II); shrinkage of the cell body (3A, III); and/or, ultimately, total loss of soma and/or dendritic GFP signal (fig. 3A, IV). Mn treatment did not significantly increase the inherent DAergic neurodegeneration in WT worms and deletion mutants (fig. 3B, a-c). Assessment of neurodegeneration at 24 and 48 hours post-treatment (larval stages) also showed no change in DAergic neurodegeneration (data not shown). However, the α -Syn-containing *pdr1* deletion mutants show a rescue in the degeneration of CEP architecture, while the α -Syn-containing *djr1.1* deletion mutants do not.

Mn-induced oxidative stress is exacerbated in *pdr1* and *djr1.1* mutants, but rescued by α -Syn expression

Oxidative stress is implicated in Mn-induced neurotoxicity⁴⁴. Additionally, *parkin*, *pink* and *djl* are all involved in regulating oxidative stress pathways⁴⁵. Therefore, we investigated the relationship between Mn, oxidative stress and defense responses by measuring the presence of RONS and total GSH levels. To determine the presence of RONS in whole worms, a carboxy-DCFH-DA based reader test system was established (data not shown). Figure 4A shows Mn-induced RONS levels in WT worms, *pdr1* and *djr1.1* mutants, along with their respective α -Syn-expressing strains. In response to sub-lethal, acute Mn treatment (respective LD₂₅), WT worms showed a time-dependent increase in Mn-induced RONS that was exacerbated in *pdr1*, *pink1* and *djr1.1* mutants (data are normalized to respective control (dye-loaded cells without a RONS generator) at each respective timepoint). As illustrated in fig. 4A (c & d), *pdr1* and *djr1.1* mutants containing α -Syn showed a lower Mn-induced RONS level compared to the non α -Syn expressing deletion mutants.

Next, GSH levels were analysed in the deletion mutants to ascertain their redox status. The deletion mutants contained significantly less total GSH than WT worms (fig. 4B). Mn treatment resulted in a slight reduction in GSH levels, which did not attain statistical significance. The significant decrease in GSH levels at 10 mM Mn in the *pdr1* mutants likely reflects Mn-induced lethality at this dose (fig. 1A). The α -Syn-containing deletion mutants showed similar effects as the deletion mutants alone (data not shown). Treatment with H₂O₂ as a positive control corroborated that the inherently decreased levels of GSH in the mutants represent an innately defective oxidative stress response, as H₂O₂ treatment did not significantly alter GSH levels from baseline levels as compared to WT worms (data not shown).

Increased *skn-1* mRNA expression in *djr1.1* and *pink1* mutants

To determine whether the differences in oxidative stress levels are associated with differences in cellular defense responses against oxidative stress, expression of the antioxidant response gene *skn-1*, the orthologue of the vertebrate gene *nrf2*⁴⁶, was examined. Gene expression data reveal inherently upregulated *skn-1* mRNA levels in the deletion mutants compared to WT worms (fig. 5A), reaching statistical significance in the *pink1* and *djr1.1* mutants. Acute Mn treatment resulted in an upregulation of *skn-1* mRNA at the LD₅₀ dose only in *djr1.1* mutants. Interestingly, the *pdr1* mutants containing α -Syn showed a trend for increased *skn-1* mRNA expression, whereas the levels were decreased in the *pink1* and *djr1.1* mutants (fig. 5B).

Decreased *dat-1* expression in *djr1.1* deletion mutants

Since previous studies supported the role of extracellular dopamine in exacerbating Mn toxicity³⁹, we further investigated possible interactions between α -Syn and the dopamine transporter (DAT), the protein responsible for synaptic DA clearance. Recent evidence points to α -Syn-mediated modulation of DAT⁴⁷ as a potential mechanism for the selectivity towards DAergic neurodegeneration in PD. Using Real Time RT PCR, we show that *pdr1* mutants have inherently higher *dat-1* mRNA levels, whereas the expression is reduced in both Mn treated and untreated *djr1.1* mutants compared to WT worms (fig. 6A). *pink1* mutants were indistinguishable from the WT worm with respect to DA neurodegeneration and *dat-1* mRNA level (data not shown).

Discussion

The specific interactions between environmental factors and various genetic deletions associated with PD pathophysiology remain poorly understood. In the present study, the invertebrate *C. elegans* model was used to examine the effects of acute Mn exposure on DAergic neurotoxicity in the background of three PD-associated genes (*pdr1/parkin*, *pink1* and *djr1.1/djl1*) in the absence or presence of WT human α -Syn. The ease in genetic manipulation and breeding of nematodes allowed for the quick generation and assessment of crosses needed to evaluate DAergic neurodegeneration. Moreover, this model system allows for an alternative approach to otherwise time-consuming and costly vertebrate models that contain intricate nervous systems, hindering more rapid investigations into neurodegenerative mechanisms.

Regarding the Mn-induced lethality in the present study, *pdr1* mutants showed the highest sensitivity to acute Mn exposure. Interestingly, vulnerability of the WT worms to acute MnCl₂ exposure has changed since our previously published paper³⁹, which may be due to the current use of MnCl₂ with a higher purity of >99.995%. Thus, new curves were generated. Based on the different dose-response of the WT worms and the deletion mutants following acute Mn exposure, we examined whether they showed a differential Mn accumulation profile compared to WT worms. Interestingly, both *pdr1* and *djr1.1* mutants displayed significantly enhanced intraworm Mn accumulation, as shown by ICP-MS/MS. Mn accumulation inside the worms (and not just a measurement of metals bound to the outer worm cuticle) was also corroborated by the novel and optimized utilization of LA-ICP-MS⁴⁸.

Our laboratory has recently identified a network of Mn transporter genes responsible for controlling Mn homeostasis in worms. The *smf1-3* genes are orthologues for the mammalian divalent metal transporter 1 (DMT1), with SMF-3 serving as the primary Mn uptake transporter in *C. elegans*⁴⁹. Interestingly, evidence has pointed to a parkin-mediated regulation of DMT1 levels via ubiquitination *in vitro*⁵⁰. As the *pdr1* gene shows conservation of its ubiquitin ligase activity in nematodes, it is plausible that the loss of *pdr1* enhanced Mn uptake due to the loss of transporter regulation. This interaction would be interesting to examine in this model system, as the *C. elegans* genome does not have nearly as many E3 ubiquitin ligases as the human genome⁵¹, reducing the amount of compensatory mechanisms that may be possible in vertebrate knockout models.

Furthermore, previous evidence in *Drosophila melanogaster* has shown increased lifespan in *parkin*-null flies upon exposure to metal chelators compared to controls, indicating a heightened sensitivity to endogenous copper (Cu²⁺) and iron (Fe²⁺) levels⁵². This interaction was further supported by evidence showing a rescue of the *parkin* null phenotype by overexpression of a metal transcription factor (MTF-1)⁵³. However, previous *C. elegans* studies in *pdr1* mutants found no increased sensitivity upon exposure to Fe²⁺ and Cu²⁺⁵⁴.

Our current findings of enhanced intraworm Mn accumulation corroborate a distinctive connection between parkin and metal homeostasis that may be Mn-specific, as we have also previously found that the same *pdr1* mutants do not show significantly increased methylmercury (MeHg) accumulation compared to WT animals ⁵⁵.

Due to the close relationship between parkin and DJ1-associated pathways, it is possible that they may be directly regulating each other. New evidence suggests a novel role for DJ1 in reducing metal-induced cytotoxicity by directly binding metals *in vitro*. While this study found a weaker binding affinity for Mn compared to Cu²⁺ and mercury (Hg²⁺) ⁵⁶, the alterations in Mn homeostasis in the worms may result in subsequent intracellular dyshomeostasis of other metals that DJ1 would typically bind to. Therefore, it is feasible that the enhancement in Mn accumulation in *djr1.1* mutants could be due to the lack of metal binding in these animals. Notably, both *pdr1* and *djr1.1* mutants showed an analogous increase in Mn accumulation, yet they possessed differential neurodegeneration profiles. Parkin has recently been shown to downregulate DJ1 protein and mRNA levels ⁵⁷, with *parkin* knockout mice showing increased DJ1 protein levels upon proteasomal inhibition ⁵⁸. The loss of parkin (*pdr1* in our case) itself may be sufficient to cause proteasomal impairment from increased oxidative stress and abnormal accumulation of misfolded proteins. This may be due to increased expression of *djr1.1* in the background of *pdr1* loss that ameliorates overall neurotoxicity in these animals.

While manganism is distinctive from PD in terms of the initial site of metal accumulation and toxicity (globus pallidus), both medical conditions implicate enhanced oxidative damage. In the absence of genetic alterations, Mn itself can cause mitochondrial damage by inhibiting complex I and II of the electron transport chain (ETC) and oxidative phosphorylation ⁵⁹. Mn can also increase isoprostane (lipid peroxidation marker) generation ⁶⁰ and decrease ATP levels in a dose-dependent manner, resulting in increased neurodegeneration ⁴⁴. The increased intraworm Mn concentrations may also influence iron (Fe) concentrations, another heavy metal that competes with Mn for transport via DMT1 and the transferrin receptor (TfR) ⁶¹. Furthermore, iron has been implicated in PD by promoting oxidative damage via the Fenton reaction or altering oxidative response pathways ⁶². Mn has also been shown to exacerbate DA oxidation to produce damaging, reactive DA intermediates ⁶³. The combination of Mn's own oxidative potential and enhancement of DA oxidation, represent a plausible mechanism for its selectivity towards DAergic neurodegeneration, as previously corroborated in *C. elegans* ³⁹.

The marked increase in baseline RONS induction in the *pdr1* mutants was striking; however, this is not surprising, as parkin's significant role in mediating mitophagy warrants impaired mitochondrial integrity in its absence ^{17a, 64}. The similarly elevated basal RONS levels in the *djr1.1* mutants do not quite reach the level of the *pdr1* mutants. As noted earlier, several studies have affirmed DJ1's role as an oxidative stress sensor, indicating that loss of DJ1 would inherently result in increased RONS production ²⁰. We posit this inherently enhanced level of RONS induction accounts for an attenuated response upon acute Mn exposure, as these mutants exhibit a ceiling effect to the already-high baseline RONS levels. Given its role in recruiting parkin to damaged mitochondria, it was somewhat unexpected that *pink1* mutants only showed a slightly enhanced RONS induction compared to WT worms. However, the presence of DJ1 in *Drosophila* is able to rescue mitochondrial deficits in the background of *pink1*, but not *parkin* loss ²⁵. This could account for the lack of an oxidative stress phenotype in the *pink1* mutants, as well as the fact that these mutants did not take up as much Mn as the *pdr1* and *djr1.1* mutants.

While a trend was apparent towards a dose-dependent effect of Mn on GSH depletion in WT animals, the deletion mutants show no significant change with treatment. In particular, the

baseline reduction in GSH levels in all deletion mutants suggests an inherently impaired ability to adapt to stressful stimuli, such as acute Mn exposure. In *pdr1* mutants, this may also relate to the inherently high levels of RONS production, as they show the lowest basal total GSH levels. Moreover, it has been shown that knocking down *pink1* in human neurons results in GSH reduction⁴⁵. Similarly, DJ1 expression promotes upregulation of glutathione synthesis⁶⁵, which corresponds with the finding in *djr1.1* mutants, showing decreased GSH levels. Taken together, our data support a mechanism of neurotoxicity through compromised clearance of Mn-damaged mitochondria due to the loss of an intact parkin/PINK1/DJ1 pathway, resulting in heightened RONS production that cannot be inherently combated due to basal GSH deficiencies in the mutants.

The observed increase in RONS induction and basal GSH depletion in mutants, showing enhanced Mn accumulation (*pdr1* and *djr1.1*) warranted further examination into whether these animals also have alterations in *skn-1* expression, the worm orthologue for *nrf2*. Nuclear factor erythroid 2-related factor 2, or Nrf2, is a transcription factor that promotes the upregulation of antioxidant genes upon oxidative-stress-induced translocation from the cytoplasm to the nucleus⁶⁶. Previous work has found *skn-1* mutants to be vulnerable to oxidative stress⁶⁷. While not significant, *pdr1* mutants showed a trend for increased *skn-1* mRNA expression, which was consistent with increased Nrf2 activity found in an induced pluripotent stem cell (iPSC) study in patients harboring *parkin* mutations⁶⁸. Moreover, contrary to DJ1 acting as an Nrf2 stabilizer⁶⁹, we found significantly increased *skn-1* mRNA expression in the *djr1.1* mutants. While we did not expect this increase, there may be a compensatory mechanism in these animals to counteract the basal GSH depletion that would otherwise protect against RONS production by upregulating *skn-1*-mediated antioxidant gene transcription.

Additionally, the enhanced oxidative stress of the *pdr1* and *djr1.1* mutants occurs in the absence of Mn-induced DAergic neurodegeneration. Similarly, the lack of subacute Mn-induced changes in the basal ganglia has been previously shown in primates⁷⁰. Thus, the findings in this study corroborate that Mn is even more relevant in exacerbating genetic risk for PD. In a previously published study from our group, Mn showed a selective effect on dopaminergic neurons in WT worms 24 hours post-treatment³⁹. This is not in conflict with the current study, given the use of a new, objective scoring for degenerated architecture of CEP neurons, along with differing Mn doses newly generated from the survival curves.

Although α -Syn is known to be involved in the pathogenesis of PD, its role in both neuroprotection and neurodegeneration is controversial. Mutated forms of α -Syn, (A30P, E46K, A53T) have been reported to be neurotoxic, while WT α -Syn has been implicated in neuroprotection⁷¹. α -Syn is a neuronal protein in vertebrates that is ubiquitously expressed at high levels in all brain regions⁷², but it is not expressed in *C. elegans*. Therefore, worms expressing human WT α -Syn were utilized to address the role of α -Syn in the mutated background of *pdr1*, *pink1* and *djr1.1* with respect to Mn homeostasis and oxidative stress.

There is increasing evidence that α -Syn interacts with metal ions, thereby affecting their homeostasis. Initial studies of the potential to bind metals came from the ability of certain metals to catalyze α -Syn aggregation⁷³. Overall, two major types of interactions between metals and α -Syn have been reported. In addition to non-specific sites of electrostatic interactions, the C-terminus contains a¹¹⁹DPDNEA motif binding site, suggesting that metal binding is driven by both electrostatic interactions and the residual structure of the α -Syn C-terminus. The C-terminal low-affinity sites have been reported to interact with different metal ions, with copper (Cu) and Fe most intensively studied⁷⁴. Although the majority of metal ions interact with α -Syn with low affinity, the protein possesses high affinity to Cu²⁺ and Fe³⁺ at the N-terminal region. Modifications by redox-active metal ions

may be relevant for the aggregation properties of α -Syn⁷⁵. A co-incubation of α -Syn with Mn^{2+} has been reported to induce partial folding of the protein and serve as an effective promoter of α -Syn aggregation⁷⁶.

In addition to its metal binding capacity, the role of α -Syn as a cellular ferrireductase has been recently identified, providing further evidence towards the multiple roles of α -Syn in metal homeostasis⁷⁷. One very important outcome of the present work is the novel role of α -Syn in altering Mn accumulation in the background of mutated *pdr1* and *djr1.1* worms, which may be partially due to an endogenous metal binding capacity. Even as α -Syn was only expressed in the DAergic neurons of the worms, the global alterations in Mn homeostasis were drastic; secretion of α -Syn into other regions cannot be excluded⁷⁸. In fact, an environmental toxin (i.e. rotenone) has been shown to promote the release of α -Syn from enteric neurons⁷⁹.

In terms of the role of α -Syn in modulating oxidative stress responses, the loss of *pdr1* or *djr1.1* in α -Syn-expressing worms resulted in reduced Mn-induced RONS production, compared to worms containing the genetic deletion alone. This effect was due to the reduced Mn accumulation in the presence of α -Syn in both *pdr1* and *djr1.1* deletion backgrounds. Additionally, attenuated oxidative stress, in accordance with the neuroprotective role of α -Syn, has been shown in cells expressing WT α -Syn, where protection against rotenone and maneb toxicity was conferred by preservation of mitochondrial function^{71b}. Additionally, WT α -Syn-expressing cells also showed the ability to attenuate decreased intracellular GSH levels upon serum deprivation⁸⁰. The results in the current study support the literature in finding a neuroprotective role of wildtype α -Syn against oxidative stress.

Since one function of α -Syn is the modulation of the dopamine transporter (DAT) and loss of *dat-1* is detrimental to worm survival following acute Mn exposure, the *dat-1* expression was investigated. This transporter (DAT-1 in *C. elegans*) is involved in synaptic neurotransmitter clearance, and especially responsible for DA reuptake to remove excessive extracellular DA concentrations⁸¹. Inhibition of DAT leads to high extracellular DA levels⁸². In *C. elegans*, we have already shown that upon Mn exposure, loss of *dat-1* increases Mn-induced lethality compared to WT worms, with extracellular DA exacerbating Mn-induced oxidative stress, lifespan reduction and DAergic neurodegeneration³⁹. While *pdr1* mutants showed inherently higher *dat-1* mRNA levels, the downregulation of *dat-1* mRNA in the *djr1.1* mutants suggests a reduced synaptic DA clearance. This might be due to the increased DAergic neurodegeneration of the α -Syn-containing *djr1.1* deletion mutants compared to the α -Syn-containing *pdr1* deletion mutants. The increased *dat-1* levels would suggest higher extracellular DA levels in the *djr1.1* mutants as a potential mechanism behind the enhanced neurodegeneration. Taken together, these findings support the role of extracellular DA in exacerbating Mn neurotoxicity.

Conclusions

The genetically amenable *C. elegans* model system was utilized to examine the neuroprotective or neurotoxic role of α -Syn in mediating Mn neurotoxicity in the background of loss in the PD-associated genes *pdr1*, *pink1* and *djr1.1*. For the first time, the current study provides evidence for a neuroprotective role of WT α -Syn against Mn accumulation and Mn-induced oxidative stress in the background of *pdr1* and *djr1.1* loss.

Acknowledgments

This work was funded by the Center in Molecular Toxicology NIH grant P30 ES00267, R01 ES10563, the training program in Environmental Toxicology grant T32 ES007028, the Josef Schormüller Award and the DFG (BO 4103/1-1). We would also like to thank the Blakely laboratory (Vanderbilt University Medical Center) for strains

and sharing resources. Lastly, we would like to thank Drs. Bill Valentine and Keith Erikson for sharing resources and scientific communications.

References

1. ATSDR. Toxicological profile for manganese (Draft for Public Comment). U.S. Department of Health and Human Services, Public Service. 2008
2. Lees AJ, Hardy J, Revesz T. Parkinson's disease. *Lancet*. 2009; 373:2055–66.10.1016/S0140-6736(09)60492-X [PubMed: 19524782]
3. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. *Neuron*. 2010; 66:646–61.10.1016/j.neuron.2010.04.034 [PubMed: 20547124]
4. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature*. 1998; 392:605–8.10.1038/33416 [PubMed: 9560156]
5. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97:13354–9.10.1073/pnas.240347797 [PubMed: 11078524]
6. Sriram SR, Li X, Ko HS, Chung KK, Wong E, Lim KL, Dawson VL, Dawson TM. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. *Human molecular genetics*. 2005; 14:2571–86.10.1093/hmg/ddi292 [PubMed: 16049031]
7. Sang TK, Chang HY, Lawless GM, Ratnaparkhi A, Mee L, Ackerson LC, Maidment NT, Krantz DE, Jackson GR. A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2007; 27:981–90.10.1523/JNEUROSCI.4810-06.2007 [PubMed: 17267552]
8. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. *The Journal of biological chemistry*. 2003; 278:43628–35.10.1074/jbc.M308947200 [PubMed: 12930822]
9. (a) Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. *Oncogene*. 2001; 20:4457–65.10.1038/sj.onc.1204608 [PubMed: 11494141] (b) Jendrach M, Gispert S, Ricciardi F, Klinkenberg M, Schemm R, Auburger G. The mitochondrial kinase PINK1, stress response and Parkinson's disease. *Journal of bioenergetics and biomembranes*. 2009; 41:481–6.10.1007/s10863-009-9256-0 [PubMed: 19941155]
10. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science*. 2004; 304:1158–60.10.1126/science.1096284 [PubMed: 15087508]
11. Sim CH, Lio DS, Mok SS, Masters CL, Hill AF, Culvenor JG, Cheng HC. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. *Human molecular genetics*. 2006; 15:3251–62.10.1093/hmg/ddl398 [PubMed: 17000703]
12. Yang Y, Ouyang Y, Yang L, Beal MF, McQuibban A, Vogel H, Lu B. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105:7070–5.10.1073/pnas.0711845105 [PubMed: 18443288]
13. Plun-Favreau H, Klupsch K, Moiso N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N, Wood NW, Martins LM, Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. *Nature cell biology*. 2007; 9:1243–52.10.1038/ncb1644

14. Petit A, Kawai T, Paitel E, Sanjo N, Maj M, Scheid M, Chen F, Gu Y, Hasegawa H, Salehi-Rad S, Wang L, Rogaeva E, Fraser P, Robinson B, St George-Hyslop P, Tandon A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. *The Journal of biological chemistry*. 2005; 280:34025–32.10.1074/jbc.M505143200 [PubMed: 16079129]
15. Gandhi S, Vaarmann A, Yao Z, Duchon MR, Wood NW, Abramov AY. Dopamine induced neurodegeneration in a PINK1 model of Parkinson's disease. *PloS one*. 2012; 7:e37564.10.1371/journal.pone.0037564 [PubMed: 22662171]
16. Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, Martella G, Bonsi P, Zhang C, Pothos EN, Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:11441–6.10.1073/pnas.0702717104 [PubMed: 17563363]
17. (a) Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J, May J, Tocilescu MA, Liu W, Ko HS, Magrane J, Moore DJ, Dawson VL, Grailhe R, Dawson TM, Li C, Tieu K, Przedborski S. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:378–83.10.1073/pnas.0911187107 [PubMed: 19966284] Kim Y, Park J, Kim S, Song S, Kwon SK, Lee SH, Kitada T, Kim JM, Chung J. PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. *Biochemical and biophysical research communications*. 2008; 377:975–80.10.1016/j.bbrc.2008.10.104 [PubMed: 18957282] (c) Okatsu K, Oka T, Iguchi M, Imamura K, Kosako H, Tani N, Kimura M, Go E, Koyano F, Funayama M, Shiba-Fukushima K, Sato S, Shimizu H, Fukunaga Y, Taniguchi H, Komatsu M, Hattori N, Mihara K, Tanaka K, Matsuda N. PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. *Nature communications*. 2012; 3:1016.10.1038/ncomms2016
18. Chen Y, Dorn GW 2nd. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. *Science*. 2013; 340:471–5.10.1126/science.1231031 [PubMed: 23620051] (b) Sun Y, Vashisht AA, Tchiew J, Wohlschlegel JA, Dreier L. Voltage-dependent anion channels (VDACs) recruit Parkin to defective mitochondria to promote mitochondrial autophagy. *The Journal of biological chemistry*. 2012; 287:40652–60.10.1074/jbc.M112.419721 [PubMed: 23060438]
19. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science*. 2003; 299:256–9.10.1126/science.1077209 [PubMed: 12446870]
20. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, Cookson MR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. *Proc Natl Acad Sci U S A*. 2004; 101:9103–8. [pii]. 10.1073/pnas.04029591010402959101 [PubMed: 15181200]
21. Wang X, Petrie TG, Liu Y, Liu J, Fujioka H, Zhu X. Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. *Journal of neurochemistry*. 2012; 121:830–9.10.1111/j.1471-4159.2012.07734.x [PubMed: 22428580]
22. Inden M, Taira T, Kitamura Y, Yanagida T, Tsuchiya D, Takata K, Yanagisawa D, Nishimura K, Taniguchi T, Kiso Y, Yoshimoto K, Agatsuma T, Koide-Yoshida S, Iguchi-Arigo SM, Shimohama S, Ariga H. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. *Neurobiology of disease*. 2006; 24:144–58.10.1016/j.nbd.2006.06.004 [PubMed: 16860563]
23. Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C, Xia K, Jiang W, Ronai Z, Zhuang X, Zhang Z. Parkin PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. *The Journal of clinical investigation*. 2009; 119:650–60.10.1172/JCI37617 [PubMed: 19229105]
24. Haque ME, Mount MP, Safarpour F, Abdel-Messih E, Callaghan S, Mazerolle C, Kitada T, Slack RS, Wallace V, Shen J, Anisman H, Park DS. Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1. *The Journal of biological chemistry*. 2012; 287:23162–70.10.1074/jbc.M112.346437 [PubMed: 22511790]

25. Hao LY, Giasson BI, Bonini NM. DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:9747–52.10.1073/pnas.0911175107 [PubMed: 20457924]
26. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science*. 1997; 276:2045–7. [PubMed: 9197268]
27. Lemkau LR, Comellas G, Lee SW, Rikardsen LK, Woods WS, George JM, Rienstra CM. Site-specific perturbations of alpha-synuclein fibril structure by the Parkinson's disease associated mutations A53T and E46K. *PloS one*. 2013; 8:e49750.10.1371/journal.pone.0049750 [PubMed: 23505409] (b) Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97:571–6. [PubMed: 10639120]
28. (a) Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2000; 20:3214–20. [PubMed: 10777786] (b) Diao J, Burre J, Vivona S, Cipriano DJ, Sharma M, Kyoung M, Sudhof TC, Brunger AT. Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. *eLife*. 2013; 2:e00592.10.7554/eLife.00592 [PubMed: 23638301]
29. Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, Aebischer P, Schneider BL. Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. *Acta neuropathologica*. 2012; 123:653–69.10.1007/s00401-012-0963-y [PubMed: 22361813]
30. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. A role for alpha-synuclein in the regulation of dopamine biosynthesis. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2002; 22:3090–9. doi: 20026307. [PubMed: 11943812]
31. Alerte TN, Akinfolarin AA, Friedrich EE, Mader SA, Hong CS, Perez RG. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. *Neuroscience letters*. 2008; 435:24–9.10.1016/j.neulet.2008.02.014 [PubMed: 18314273]
32. Aschner JL, Aschner M. Nutritional aspects of manganese homeostasis. *Molecular aspects of medicine*. 2005; 26:353–62.10.1016/j.mam.2005.07.003 [PubMed: 16099026]
33. (a) Guilarte TR. Manganese and Parkinson's disease: a critical review and new findings. *Environmental health perspectives*. 2010; 118:1071–80. doi: 10.1289/ehp.0901748. [PubMed: 20403794] (b) Aschner M, Erikson KM, Herrero Hernandez E, Tjalkens R. Manganese and its role in Parkinson's disease: from transport to neuropathology. *Neuromolecular medicine*. 2009; 11:252–66.10.1007/s12017-009-8083-0 [PubMed: 19657747] (c) Racette BA. Manganism in the 21st century: The Hanninen lecture. *Neurotoxicology*. 2013 doi: S0161-813X1300157-5[pii] 10.1016/j.neuro.2013.09.007. (d) Tuschl K, Mills PB, Clayton PT. Manganese and the brain. *Int Rev Neurobiol*. 2013; 110:277–312. doi: 10.1016/B978-0-12-410502-7.00013-2 B978-0-12-410502-7.00013-2[pii]. [PubMed: 24209443]
34. Burton NC, Guilarte TR. Manganese neurotoxicity: lessons learned from longitudinal studies in nonhuman primates. *Environmental health perspectives*. 2009; 117:325–32. doi:10.1289/ehp.0800035. [PubMed: 19337503]
35. Sriram K, Lin GX, Jefferson AM, Roberts JR, Wirth O, Hayashi Y, Krajnak KM, Soukup JM, Ghio AJ, Reynolds SH, Castranova V, Munson AE, Antonini JM. Mitochondrial dysfunction and loss of Parkinson's disease-linked proteins contribute to neurotoxicity of manganese-containing welding fumes. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2010; 24:4989–5002.10.1096/fj.10-163964 [PubMed: 20798247]

36. Higashi Y, Asanuma M, Miyazaki I, Hattori N, Mizuno Y, Ogawa N. Parkin attenuates manganese-induced dopaminergic cell death. *Journal of neurochemistry*. 2004; 89:1490–7.10.1111/j.1471-4159.2004.02445.x [PubMed: 15189352]
37. Brenner S. The genetics of *Caenorhabditis elegans*. *Genetics*. 1974; 77:71–94. [PubMed: 4366476]
38. Boumans, PWJM. Inductively Coupled Plasma Emission Spectroscopy, Part 2: Applications And Fundamentals. John Wiley & Sons; New York: 1987.
39. Benedetto A, Au C, Avila DS, Milatovic D, Aschner M. Extracellular dopamine potentiates mn-induced oxidative stress, lifespan reduction, and dopaminergic neurodegeneration in a BLI-3-dependent manner in *Caenorhabditis elegans*. *PLoS genetics*. 2010; 6:10.1371/journal.pgen.1001084
40. (a) Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. *Nat Protoc*. 2006; 1:3159–65. nprot.2006.378 [pii]. 10.1038/nprot.2006.378 [PubMed: 17406579] (b) Caito SW, Valentine WM, Aschner M. Dopaminergic neurotoxicity of S-ethyl N,N-dipropylthiocarbamate (EPTC), molinate, and S-methyl-N,N-diethylthiocarbamate (MeDETC) in *Caenorhabditis elegans*. *J Neurochem*. 2013 10.1111/jnc.12349. 10.1111/jnc.12349
41. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*. 2001; 25:402–8. S1046-2023(01)91262-9 [pii]. 10.1006/meth.2001.1262 [PubMed: 11846609]
42. (a) WormBase.org. http://www.wormbase.org/species/c_elegans/gene/WBGene00015184#0-9d6-3 (b) Lee JY, Song J, Kwon K, Jang S, Kim C, Baek K, Kim J, Park C. Human DJ-1 and its homologs are novel glyoxalases. *Human molecular genetics*. 2012; 21:3215–25.10.1093/hmg/dds155 [PubMed: 22523093]
43. Jayanthi LD, Apparsundaram S, Malone MD, Ward E, Miller DM, Eppler M, Blakely RD. The *Caenorhabditis elegans* gene T23G5.5 encodes an antidepressant- and cocaine-sensitive dopamine transporter. *Molecular pharmacology*. 1998; 54:601–9. [PubMed: 9765501]
44. Milatovic D, Zaja-Milatovic S, Gupta RC, Yu Y, Aschner M. Oxidative damage and neurodegeneration in manganese-induced neurotoxicity. *Toxicology and applied pharmacology*. 2009; 240:219–25.10.1016/j.taap.2009.07.004 [PubMed: 19607852]
45. Wilhelmus MM, Nijland PG, Drukarch B, de Vries HE, van Horssen J. Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders. *Free radical biology & medicine*. 2012; 53:983–92.10.1016/j.freeradbiomed.2012.05.040 [PubMed: 22687462]
46. Oliveira RP, Porter Abate J, Dilks K, Landis J, Ashraf J, Murphy CT, Blackwell TK. Condition-adapted stress and longevity gene regulation by *Caenorhabditis elegans* SKN-1/Nrf. *Aging cell*. 2009; 8:524–41. ACE501 [pii]. 10.1111/j.1474-9726.2009.00501.x [PubMed: 19575768]
47. Swant J, Goodwin JS, North A, Ali AA, Gamble-George J, Chirwa S, Khoshbouei H. alpha-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. *The Journal of biological chemistry*. 2011; 286:43933–43.10.1074/jbc.M111.241232 [PubMed: 21990355]
48. Becker JS, Zoriy MV, Pickhardt C, Palomero-Gallagher N, Zilles K. Imaging of copper, zinc, and other elements in thin section of human brain samples (hippocampus) by laser ablation inductively coupled plasma mass spectrometry. *Analytical chemistry*. 2005; 77:3208–16.10.1021/ac040184q [PubMed: 15889910]
49. Au C, Benedetto A, Anderson J, Labrousse A, Erikson K, Ewbank JJ, Aschner M. SMF-1, SMF-2 and SMF-3 DMT1 orthologues regulate and are regulated differentially by manganese levels in *C. elegans*. *PloS one*. 2009; 4:e7792.10.1371/journal.pone.0007792 [PubMed: 19924247]
50. Roth JA, Singleton S, Feng J, Garrick M, Paradkar PN. Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. *Journal of neurochemistry*. 2010; 113:454–64.10.1111/j.1471-4159.2010.06607.x [PubMed: 20089134]
51. Kipreos ET. Ubiquitin-mediated pathways in *C. elegans*. *WormBook : the online review of C elegans biology*. 2005:1–24.10.1895/wormbook.1.36.1 [PubMed: 18050424]
52. Saini N, Oelhafen S, Hua H, Georgiev O, Schaffner W, Bueler H. Extended lifespan of *Drosophila parkin* mutants through sequestration of redox-active metals and enhancement of anti-oxidative

- pathways. *Neurobiology of disease*. 2010; 40:82–92.10.1016/j.nbd.2010.05.011 [PubMed: 20483372]
53. Saini N, Georgiev O, Schaffner W. The parkin mutant phenotype in the fly is largely rescued by metal-responsive transcription factor (MTF-1). *Molecular and cellular biology*. 2011; 31:2151–61.10.1128/MCB.05207-11 [PubMed: 21383066]
 54. Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM, Alfonso A, Steer C, Liu L, Przedborski S, Wolozin B. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in *Caenorhabditis elegans*. *The Journal of biological chemistry*. 2005; 280:42655–68.10.1074/jbc.M505910200 [PubMed: 16239214]
 55. Martinez-Finley EJ, Chakraborty S, Slaughter JC, Aschner M. Early-Life Exposure to Methylmercury in Wildtype and pdr-1/parkin Knockout *C. elegans*. *Neurochemical research*. 2013; 38:1543–52.10.1007/s11064-013-1054-8 [PubMed: 23609499]
 56. Bjorkblom B, Adilbayeva A, Maple-Groden J, Piston D, Okvist M, Xu XM, Brede C, Larsen JP, Moller SG. Parkinson Disease Protein DJ-1 Binds Metals and Protects against Metal-induced Cytotoxicity. *The Journal of biological chemistry*. 2013; 288:22809–20.10.1074/jbc.M113.482091 [PubMed: 23792957]
 57. Duplan E, Giaime E, Viotti J, Sevalle J, Corti O, Brice A, Ariga H, Qi L, Checler F, Alves da Costa C. ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1. *Journal of cell science*. 2013; 126:2124–33.10.1242/jcs.127340 [PubMed: 23447676]
 58. Casarejos MJ, Solano RM, Rodriguez-Navarro JA, Gomez A, Perucho J, Castano JG, Garcia de Yebenes J, Mena MA. Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis. *Journal of neurochemistry*. 2009; 110:1523–37.10.1111/j.1471-4159.2009.06248.x [PubMed: 19549073]
 59. (a) Gavin CE, Gunter KK, Gunter TE. Mn²⁺ sequestration by mitochondria and inhibition of oxidative phosphorylation. *Toxicology and applied pharmacology*. 1992; 115:1–5. [PubMed: 1631887] (b) Liu Y, Barber DS, Zhang P, Liu B. Complex II of the mitochondrial respiratory chain is the key mediator of divalent manganese-induced hydrogen peroxide production in microglia. *Toxicol Sci*. 2013; 132:298–306. 10.1093/toxsci/kfs344 kfs344[pil]. [PubMed: 23315522]
 60. Cordova FM, Aguiar AS Jr, Peres TV, Lopes MW, Goncalves FM, Pedro DZ, Lopes SC, Pilati C, Prediger RD, Farina M, Erikson KM, Aschner M, Leal RB. Manganese-exposed developing rats display motor deficits and striatal oxidative stress that are reversed by Trolox. *Arch Toxicol*. 2013; 87:1231–44.10.1007/s00204-013-1017-5 [PubMed: 23385959]
 61. Erikson KM, Syversen T, Aschner JL, Aschner M. Interactions between excessive manganese exposures and dietary iron-deficiency in neurodegeneration. *Environmental toxicology and pharmacology*. 2005; 19:415–21.10.1016/j.etap.2004.12.053 [PubMed: 21783506]
 62. (a) Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, Duyckaerts C, Sazdovitch V, Zhao L, Garrick LM, Nunez MT, Garrick MD, Raisman-Vozari R, Hirsch EC. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105:18578–83.10.1073/pnas.0804373105 [PubMed: 19011085] (b) Fitsanakis VA, Zhang N, Avison MJ, Erikson KM, Gore JC, Aschner M. Changes in dietary iron exacerbate regional brain manganese accumulation as determined by magnetic resonance imaging. *Toxicological sciences : an official journal of the Society of Toxicology*. 2011; 120:146–53.10.1093/toxsci/kfq376 [PubMed: 21177776]
 63. (a) Snyder RD, Friedman MB. Enhancement of cytotoxicity and clastogenicity of l-DOPA and dopamine by manganese and copper. *Mutation research*. 1998; 405:1–8. [PubMed: 9729232] (b) Sistrunk SC, Ross MK, Filipov NM. Direct effects of manganese compounds on dopamine and its metabolite Dopac: an in vitro study. *Environmental toxicology and pharmacology*. 2007; 23:286–96.10.1016/j.etap.2006.11.004 [PubMed: 18449324]
 64. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. Mitochondrial dysfunction in *Drosophila* PINK1 mutants is complemented by parkin. *Nature*. 2006; 441:1157–61.10.1038/nature04788 [PubMed: 16672980]

65. Miyama A, Saito Y, Yamanaka K, Hayashi K, Hamakubo T, Noguchi N. Oxidation of DJ-1 induced by 6-hydroxydopamine decreasing intracellular glutathione. *PloS one*. 2011; 6:e27883.10.1371/journal.pone.0027883 [PubMed: 22132160]
66. (a) Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. *Proceedings of the National Academy of Sciences of the United States of America*. 1994; 91:9926–30. [PubMed: 7937919] (b) McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. *The Journal of biological chemistry*. 2003; 278:21592–600.10.1074/jbc.M300931200 [PubMed: 12682069]
67. An JH, Blackwell TK. SKN-1 links *C. elegans* mesendodermal specification to a conserved oxidative stress response. *Genes & development*. 2003; 17:1882–93.10.1101/gad.1107803 [PubMed: 12869585]
68. Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, Nihira T, Kobayashi T, Ohya M, Sato S, Takanashi M, Funayama M, Hirayama A, Soga T, Hishiki T, Suematsu M, Yagi T, Ito D, Kosakai A, Hayashi K, Shouji M, Nakanishi A, Suzuki N, Mizuno Y, Mizushima N, Amagai M, Uchiyama Y, Mochizuki H, Hattori N, Okano H. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. *Molecular brain*. 2012; 5:35.10.1186/1756-6606-5-35 [PubMed: 23039195]
69. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. *Proceedings of the National Academy of Sciences of the United States of America*. 2006; 103:15091–6.10.1073/pnas.0607260103 [PubMed: 17015834]
70. Suzuki Y, Mouri T, Nishiyama K, Fujii N. Study of subacute toxicity of manganese dioxide in monkeys. *Tokushima J Exp Med*. 1975; 22:5–10. [PubMed: 821178]
71. (a) Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. *Nat Med*. 2002; 8:600–6. nm0602-600 [pii]. 10.1038/nm0602-600 [PubMed: 12042811] (b) Choong CJ, Say YH. Neuroprotection of alpha-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K. *Neurotoxicology*. 2011; 32:857–63. S0161-813X(11)00101-X [pii]. 10.1016/j.neuro.2011.05.012 [PubMed: 21658409] (c) Sidhu A, Wersinger C, Moussa CE, Vernier P. The role of alpha-synuclein in both neuroprotection and neurodegeneration. *Ann N Y Acad Sci*. 2004; 1035:250–70. 1035/1/250 [pii]. 10.1196/annals.1332.016 [PubMed: 15681812]
72. (a) George JM. The synucleins. *Genome Biol*. 2002; 3 REVIEWS3002. (b) Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. *Trends Neurosci*. 1998; 21:249–54. S0166-2236(97)01213-7 [pii]. [PubMed: 9641537]
73. Brown DR. Interactions between metals and alpha-synuclein--function or artefact? *FEBS J*. 2007; 274:3766–74. EJB5917 [pii]. 10.1111/j.1742-4658.2007.05917.x [PubMed: 17617226]
74. (a) Binolfi A, Rasia RM, Bertocini CW, Ceolin M, Zweckstetter M, Griesinger C, Jovin TM, Fernandez CO. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. *J Am Chem Soc*. 2006; 128:9893–901.10.1021/ja0618649 [PubMed: 16866548] (b) Santner A, Uversky VN. Metalloproteomics and metal toxicology of alpha-synuclein. *Metallomics*. 2010; 2:378–92.10.1039/b926659c [PubMed: 21072383]
75. (a) Bisaglia M, Tessari I, Mammi S, Bubacco L. Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. *Neuromolecular Med*. 2009; 11:239–51.10.1007/s12017-009-8082-1 [PubMed: 19669606] (b) Ahmad A, Burns CS, Fink AL, Uversky VN. Peculiarities of copper binding to alpha-synuclein. *J Biomol Struct Dyn*. 2012; 29:825–42. c4315/c4317/Peculiarities-of-Copper-Binding-to--Synuclein-p18381.html [pii]. 10.1080/073911012010525023 [PubMed: 22208282]

76. (a) Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. *The Journal of biological chemistry*. 2001; 276:44284–96. M105343200 [pii]. 10.1074/jbc.M105343200 [PubMed: 11553618] (b) Verina T, Schneider JS, Guilarte TR. Manganese exposure induces alpha-synuclein aggregation in the frontal cortex of non-human primates. *Toxicol Lett*. 2013; 217:177–83. 10.1016/j.toxlet.2012.12.006S0378-4274(12)01424-5 [pii]. [PubMed: 23262390]
77. Davies P, Moualla D, Brown DR. Alpha-synuclein is a cellular ferredoxin. *PloS one*. 2011; 6:e15814.10.1371/journal.pone.0015814 [PubMed: 21249223]
78. (a) Melachroinou K, Xilouri M, Emmanouilidou E, Masgrau R, Papazafiri P, Stefanis L, Vekrellis K. Deregulation of calcium homeostasis mediates secreted alpha-synuclein-induced neurotoxicity. *Neurobiol Aging*. 2013 S0197-4580(13)00261-3 [pii]. 10.1016/j.neurobiolaging.2013.06.006(b) Emmanouilidou E, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. *Neurobiol Aging*. 2010; 31:953–68. S0197-4580(08)00252-2 [pii]. 10.1016/j.neurobiolaging.2008.07.008 [PubMed: 18715677]
79. Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O'Sullivan GA, Pal A, Said J, Marsico G, Verbavatz JM, Rodrigo-Angulo M, Gille G, Funk RH, Reichmann H. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. *Sci Rep*. 2012; 2:898.10.1038/srep00898 [PubMed: 23205266]
80. Lee M, Hyun D, Halliwell B, Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. *J Neurochem*. 2001; 76:998–1009. [PubMed: 11181819]
81. (a) Shimada S, Kitayama S, Lin CL, Patel A, Nanthakumar E, Gregor P, Kuhar M, Uhl G. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. *Science*. 1991; 254:576–8. [PubMed: 1948034] (b) Cass WA, Zahniser NR, Flach KA, Gerhardt GA. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. *J Neurochem*. 1993; 61:2269–78. [PubMed: 8245977] (c) Kilty JE, Lorang D, Amara SG. Cloning and expression of a cocaine-sensitive rat dopamine transporter. *Science*. 1991; 254:578–9. [PubMed: 1948035]
82. (a) Huotari M, Santha M, Lucas LR, Karayiorgou M, Gogos JA, Mannisto PT. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. *J Pharmacol Exp Ther*. 2002; 303:1309–16.10.1124/jpet.102.043042 [PubMed: 12438556] (b) McDonald PW, Hardie SL, Jessen TN, Carvelli L, Matthies DS, Blakely RD. Vigorous motor activity in *Caenorhabditis elegans* requires efficient clearance of dopamine mediated by synaptic localization of the dopamine transporter DAT-1. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2007; 27:14216–27. 27/51/14216 [pii]. 10.1523/JNEUROSCI.2992-07.2007 [PubMed: 18094261]

Fig. 1. *pdr1* mutants are hypersensitive to an acute Mn exposure

(A,B) Doseresponse survival curves following acute Mn exposure and the respective LD₅₀ doses. All values were compared to non-treated worms set to 100% survival and plotted against the logarithmic scale of the used Mn concentrations. (A) N2 (wildtype, WT) and *pdr1*, *pink1* and *djr1.1* deletion mutants were treated for 30 min at L1 (larval) stage with increasing concentrations of MnCl₂. (B) UA44 (WT; human α -Syn), UA88 (*pdr1* KO; human α -Syn), UA86 (*pink1* KO; human α -Syn) and UA84 (*djr1.1* KO; human α -Syn) were treated for 30 min at L1 stage with increasing concentrations of MnCl₂. (A,B) Data are expressed as means $\pm$ SEM from at least four independent experiments. Statistical analysis of the LD₅₀: ** p < 0.01 versus respective wildtype worms. (C) Statistical comparison of respective non- α -Syn and α -Syn containing worms: * p < 0.05. KO = deletion mutants.

Fig. 2. Enhanced Mn accumulation in *pdr1* and *djr1.1* mutants is reversed by WT α-Syn expression

(A-D) Intraworm Mn content after acute treatment with MnCl₂ was quantified by ICP-MS/MS. All values were normalized to non-treated wildtype (WT) worms. (A) N2 (WT) and *pdr1*, *pink1* and *djr1.1* deletion mutants were treated at L1 stage for 30 min with increasing concentrations of MnCl₂. (B) UA44 (WT; human α-Syn), UA88 (*pdr1* KO; human α-Syn), UA86 (*pink1* KO; human α-Syn) and UA84 (*djr1.1* KO; human α-Syn) were treated at L1 stage for 30 min with increasing concentrations of MnCl₂. (C) Comparing intraworm Mn content of *pdr1* mutants and UA88 (*pdr1* KO; human α-Syn) after 30 min treatment with MnCl₂ (data from A,B). (D) Comparing intraworm Mn content in *djr1.1* mutants and UA84 (*djr1.1* KO; human α-Syn) after 30 min treatment with MnCl₂ (data from A,B). (A-D) Data are expressed as means + SEM from at least six independent experiments. Statistical analysis by two-way ANOVA: (A) interaction p < 0.001, genotype p < 0.001, concentration p < 0.001; (B) interaction ns, genotype p < 0.001, concentration p < 0.001; (C) interaction ns, genotype ns, concentration p < 0.001; (D) interaction p < 0.001, genotype p < 0.001, concentration p < 0.001. ***p < 0.001, **p < 0.01, *p < 0.05. (E) 2D images and respective microscope images of WT worms (I, nontreated; II, 10 mM MnCl₂); *djr1.1* deletion mutants (III) and UA84 (*djr1.1* KO; human α-Syn) (IV) incubated with 10 mM MnCl₂ for 30 min. KO = deletion mutants; ns = not significant.

Fig. 3. Absence of Mn-induced DAergic neurodegeneration

(A) Representative confocal images used in the scoring system: normal worms (I), worms showing puncta (II), shrunken soma (III) or loss of dendrites and soma (IV). (B) The CEP architecture of 15 worms per group of WT, *pdr1* and *djr1.1* mutants and the respective α -Syncontaining strains (UA44, UA86, UA88) were scored 72 hours after an acute, 30 min treatment with MnCl₂. Shown are mean values + SEM of at least four experiments each. * p < 0.05 versus respective non-treated worms without α -Syn. KO = deletion mutants; ns = not significant.

Fig. 4. Mn-induced oxidative stress is exacerbated in *pdr1* and *djr1.1* mutants, but rescued by α -Syn expression

(A) (a) Effect of MnCl₂ on the RONS induction in N2 (WT) and *pdr1*, *pink1* and *djr1.1* deletion mutants after 1 h dye loading and subsequent MnCl₂ post-treatment with their respective LD₂₅ doses. (b) Effect of MnCl₂ on the RONS induction of UA44 (WT; human α -Syn), UA88 (*pdr1* KO; human α -Syn), UA86 (*pink1* KO; human α -Syn) and UA84 (*djr1.1* KO; human α -Syn) after 1 h dye loading and subsequent MnCl₂ post-treatment with their respective LD₂₅ doses. (c) Comparing Mn-induced RONS induction of *pdr1* mutants and UA88 (*pdr1* KO; human α -Syn) (see B,a and B,b). (d) Comparing Mn-induced RONS induction of *djr1.1* mutants and UA84 (*djr1.1* KO; human α -Syn) (see B,a and B,b). (A) Shown are mean values (+ SEM) of at least four measurements, which were normalized to the respective dye-loaded worms at the respective time-point. Statistical analysis by two-way ANOVA: (a,b,c) interaction $p < 0.001$, genotype $p < 0.001$, time $p < 0.001$; (d) interaction ns, genotype $p < 0.001$, time $p < 0.001$. (B) Total glutathione level of N2 (WT) and *pdr1*, *pink1* and *djr1.1* deletion mutants following 30 min exposure with increasing concentrations of MnCl₂. Data are expressed as means + SEM from at least five independent experiments. Statistical analysis by two-way ANOVA: interaction ns, genotype $p < 0.001$, concentration $p < 0.01$. (A-C) $p < 0.001$. *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$. KO = deletion mutants; ns = not significant.

Fig. 5. Increased *skn-1* mRNA expression in *djr1.1* and *pink1* mutants

SKN-1 expression after acute treatment with MnCl_2 . Relative gene expression was determined by qRT-PCR. (A) N2 (WT) and *pdr1*, *pink1* and *djr1.1* deletion mutants were treated at L1 stage for 30 min with MnCl_2 at the respective LD₂₅ and LD₅₀ doses. (B) UA44 (WT; human α -Syn), UA88 (*pdr1* KO; human α -Syn), UA86 (*pink1* KO; human α -Syn) and UA84 (*djr1.1* KO; human α -Syn) were treated at L1 stage for 30 min with MnCl_2 at the respective LD₂₅ and LD₅₀ doses. (A, B) Shown are mean values $\pm$ SEM of four independent experiments in duplicates normalized to the untreated wildtype and relative to *afid-1*/ β -actin mRNA. Statistical analysis by two-way ANOVA: (A) interaction ns, genotype $p < 0.01$, concentration; (B) interaction ns, genotype ns, concentration ns. ** $p < 0.01$, * $p < 0.05$ versus respective wildtype worms. KO = deletion mutants; ns = not significant.

Fig. 6. Decreased *dat-1* expression in *djr1.1* deletion mutants - *dat-1*
dat-1 mRNA expression after acute treatment with MnCl_2 . Relative gene expression was determined by qRT-PCR. UA44 (WT; human α -Syn), UA88 (*pdr1* KO; human α -Syn)) and UA84 (*djr1.1* KO; human α -Syn) were treated at L1 stage for 30 min with MnCl_2 at the respective LD₅₀. Data are expressed as means + SEM from at least four independent experiments in duplicates normalized to the untreated wildtype and relative to *afd-1*/ β -actin mRNA. Statistical analysis by two-way ANOVA: interaction ns, genotype $p < 0.001$, concentration ns. *** $p < 0.001$, * $p < 0.05$ versus respective wildtype worms. KO = deletion mutants; ns = significant.

Table 1
Conditions for ICP-MS/MS (Agilent 8800 ICP-QQQ)

Power	1550 W
Plasma gas	15 L/min
Carrier gas	1.0 L/min
Auxiliary gas	0.9 L/min
Scan mode	single quad
Q1	ion guide
Collision cell gas flow	He: 4.5 mL/min (purity: > 99.999 %) H ₂ : 0.5 mL/min (purity: > 99.999 %)
Q2	⁵⁵ Mn, ¹⁰³ Rh (ISTD)
Integration Time	1.0 s
Replicates	5

Table 2
Conditions for ICP-MS (ICAP Qc, Thermo Fisher Scientific)

Power	1550 W
Nebulizer Flow	780 mL/min
Cool Flow	14.0 L/min
Auxilliary Flow	500 mL/min
Measurement mode	KEDS
Cell gas flow	4.6 mL/min

Table 3
Conditions for LA (LSX213G2+, CETAC Technologies)

Repetition frequency	20 Hz
Spot diameter	4 μm
Scan rate	4 $\mu\text{m/s}$
He-flow 1	500 mL/min
He-flow 2	300 mL/min
Additional Ar-flow	400 mL/min